Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.

Azitra, Inc.

Azitra develops novel therapeutics to treat adverse skin conditions and disease using microbial and genetic engineering approaches for precision dermatology.

Azitra

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information visit www.azitrainc.com.

National Institutes of Health

National Science Foundation

U.S. Department of Defense

Bios Partners

Connecticut Innovations

Godfrey Capital

KdT Ventures

Leaps by Bayer

Sahsen Ventures

Azitra Inc

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

https://lnkd.in/eb2fzkQd

Azitra Inc (NYSE American: AZTR) Announces Pricing of $10.0 Million Public Offering. Maxim Group LLC is acting as the exclusive placement agent.

Read the full press release: https://lnkd.in/eiM4dhwu

Brad Hoffman, Danny Fossey, Robert Solomon, Stephen Polsinelli

Today, we're announcing the strengthening of our IP portfolio with a newly issued US patent and three additional patent allowances globally. 

Read more here:

https://lnkd.in/eNAB7rMF

We'll be at the Foundation for Foundation for Ichthyosis & Related Skin Types, Inc. (FIRST) conference this weekend to connect with patients and share about our clinical trial for Netherton syndrome at Azitra.

#FIRSTNC24 #NethertonSyndrome

We'll be at the Society of Investigative Dermatology this Friday in Dallas presenting new data on our platform and ATR-04

This Friday, we'll be presenting new data on our platform and Netherton syndrome program at ASGCT 2024. Stop by if you'll be there! 

https://lnkd.in/e_j2riaH

Today, we’re announcing the issuance of a new patent to strengthen our IP position and bolster our platform for precision dermatology.

https://lnkd.in/eMWwZqVn

Metric
Company Name	Azitra, Inc.
Symbol	AZTR
MSH ID	COM:AZITRAINC
Market	STOCKS
Sector
Industry
Country	US
Stage
Employee Count	10
Website	azitrainc.com
LinkedIn	azitra-inc
Founders

Metric
Market Cap	3.67M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	686K
Revenue (LTM)
Revenue (NTM)
Gross Profit	686K
EBITDA	-10.67M
Operating Income	-7.62M
Net Income	-11.28M
EPS	-1.63
Diluted EPS	-1.63
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1
Operating Profit Margin	-11.11
EBITDA Margin	-15.56
Net Profit Margin	-16.45
Return on Equity	1.95
Return on Assets	-1.94
Return on Capital Employed	-1.88

AZTR

COM:AZITRAINC

Azitra

Last Close

0.47

22/11 21:00

Market Cap

3.16M

Beta: -

Volume Today

128.73K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.90
P/B Ratio	2.18
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	13.82
EV Multiple	-0.26

Metric
Days Sales Outstanding	31.60
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle	100.05
Cash Conversion Cycle
Asset Turnover	0.13

Metric
Operating Cash Flow	-7.36M
Free Cash Flow	-7.68M
Cash Flow to Debt	-8.31
Operating Cash Flow/Sales	-10.73
Free Cash Flow Yield	-0.62

Metric
Cash & Equivalents	1.80M
Accounts Receivable	84.56K
Inventory	-215.22K
Goodwill
Debt to Capitalization	0.30
Debt to Assets	0.13
Current Ratio	3.35
Quick Ratio	2.91

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.23
R&D to Revenue	6.17
SG&A to Revenue	7.18